Innovations and challenges in melanoma: summary statement from the first Cambridge conference

Clinical Cancer Research

Volumn 12, Issue 7 II, 2006, Pages

  Atkins, Michael B ^a   Elder, David E ^c   Essner, Richard ^d   Flaherty, Keith T ^c   Gajewski, Thomas F ^e   Haluska, Frank G ^b   Hwu, Patrick ^f   Keilholz, Ulrich ^g   Kirkwood, John M ^h   Mier, James W ^a   Ross, Merrick I ^f   Slingluff, Craig L ⁱ   Sondak, Vernon K ^j   Sosman, Jeffrey A ^k   Weinstock, Martin A ^l   King, Laura ^m  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHN WAYNE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l BROWN UNIVERSITY   (United States)

^m InforMEDical Communications Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CANVAXIN; CARBOPLATIN; DACARBAZINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; IMATINIB; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPHAGE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG MIXTURE; DRUG MONITORING; DRUG POTENTIATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL EDUCATION; MELANOMA; NONHUMAN; PHYSICIAN; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY;

HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 33646255945     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2560     Document Type: Conference Paper

References (38)

1. Weinstock MA. Early detection of melanoma. JAMA 2000;284:886-9.
2. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985;35:130-51.
3. Mikkilineni R, Weinstock MA, Goldstein MG, Dube CE, Rossi JS. Impact of the Basic Skin Cancer Triage Curriculum on providers' skin cancer control practices. J Gen Intern Med 2001;16:302-7.
4. Weinstock MA, Risica PM, Martin RA, et al. Reliability of assessment and circumstances of performance of thorough skin self-examination for the early detection of melanoma in the Check-It-Out Project. Prev Med 2004;38:761-5.
5. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230:453-65.
6. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive non-sentinel lymph nodes after tumor-positive sentinel node dissection for melanoma. J Clin Oncol 2004;22:3677-84.
7. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004;86:212-23.
8. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-13.
9. Morton DL, Thompson JF, Cochran AJ, et al. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma [abstract 7500]. J Clin Oncol 2005;23:710S.
10. Pardoll D, Alison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004;10:887-92.
11. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13:401-7.
12. Motl SE. Technology evaluation: Canvaxin, John Wayne Cancer Institute/Cancer Vax. Curr Opin Mol Ther 2004;6:104-11.
13. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
14. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
15. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604.
16. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001;182:68-79.
17. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002;129:263-76.
18. + T-cell antigen receptor alpha chain in mice. Proc Natl Acad Sci U S A 1991;88:7518-22.
19. - T cells. J Exp Med 1994;180:1171-6.
20. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
21. van der Vliet HJ, Molling JW, von Blomberg BM, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8-23.
22. Kawano T, Nakayama T, Kamada N, et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999;59:5102-5.
23. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-gamma production by invariant NK Tcells in advanced cancer. J Immunol 2001;167:4046-50.
24. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of Valpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002;168:6494-9.
25. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 2003;122:617-22.
26. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002;51:293-8.
27. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72.
28. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756-60.
29. Otsuji M, Kimura Y, Aoe T Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996;93:13119-24.
30. Zha YY, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004;24:229-38.
31. + T cells. Cancer Res 2004;64:1140-5.
32. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
33. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. J Clin Oncol 2004;22:7506.
34. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 2004;22:7507.
35. Smalley KS, Eisen T. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin melanoma cells. Int J Cancer 2003;105:165-75.
36. DiPaola RS, Kuczynski WI, Onodera K, et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1997;4:176-82.
37. Furuhashi M, Sjoblom T, Abramsson A, et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004;64:2725-33.
38. Eton O, Billings L, Kim K, et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 2004;22:7528.